Clinical Trials Logo

Clinical Trial Summary

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.


Clinical Trial Description

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%. Immunosuppression reduction is the management cornerstone for BKV and has been shown to be effective at clearing the virus while maintaining graft function in both kidney alone and simultaneous kidney-pancreas transplant recipients. However, there is a lack of published data on the prevalence and outcomes in simultaneous liver-kidney (SLK) transplant recipients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05224583
Study type Observational
Source Methodist Health System
Contact
Status Enrolling by invitation
Phase
Start date November 17, 2021
Completion date November 17, 2022

See also
  Status Clinical Trial Phase
Terminated NCT02439957 - A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Phase 3
Not yet recruiting NCT06364618 - Use of Wearables to Detect Infections in Kidney Transplant Recipients
Completed NCT05142748 - Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03339661 - Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring. Phase 2
Recruiting NCT04701528 - Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients Phase 2
Recruiting NCT04494776 - SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
Completed NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children Phase 3
Recruiting NCT06219616 - Prediction of BK Virus Reactivation in Kidney Transplant Recipient N/A
Not yet recruiting NCT05708534 - Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
Recruiting NCT03488771 - Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
Recruiting NCT04815954 - Early vs Late Urinary Catheter Removal After Renal Transplantation N/A
Recruiting NCT05727709 - Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
Completed NCT04542954 - Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
Active, not recruiting NCT03924219 - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Recruiting NCT05836636 - Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
Not yet recruiting NCT06407232 - Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients Phase 3
Completed NCT03468478 - Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Phase 4
Recruiting NCT05397821 - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Not yet recruiting NCT05316038 - Metabolic and Infectious Complications Post Belatacept Conversion